ScripMerck & Co. is expanding into yet another therapeutic area with the $10bn acquisition of the UK biopharma Verona Pharma, part of the company’s continued effort to diversify outside of oncology and
Pink SheetThe consumer representative for the US Food and Drug Administration’s Pediatric Advisory Committee said the adverse event reporting system needs improvement and the agency’s postmarketing surveillance
ScripThe UK’s Verona Pharma, long touted as a takeover target on the back of an impressive launch of its chronic obstructive pulmonary disorder drug, Ohtuvayre, is to be acquired by Merck & Co in a d
ScripThe recent removal of the Risk Evaluation and Mitigation Strategies (REMS) requirement for approved cellular CAR-T therapies for cancer was lauded as an expansion of the market from the two-in-10 el